Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.

[1]  A. Gottlieb,et al.  Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. , 2013, Journal of drugs in dermatology : JDD.

[2]  G. Schett,et al.  Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. , 2012, Arthritis and rheumatism.

[3]  K. Papp,et al.  Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial , 2012, The Lancet.

[4]  P. Haslett,et al.  IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. , 2012, The Journal of allergy and clinical immunology.

[5]  P. Schafer Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. , 2012, Biochemical Pharmacology.

[6]  S. Karasawa,et al.  Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide , 2012, Leukemia.

[7]  M. Abdollahi,et al.  Phosphodiesterase inhibitors in inflammatory bowel disease , 2012, Expert opinion on investigational drugs.

[8]  T. Palmer,et al.  Unbiased identification of substrates for the Epac1-inducible E3 ubiquitin ligase component SOCS-3. , 2012, Biochemical Society transactions.

[9]  J. Corbin,et al.  Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. , 2011, Physiological reviews.

[10]  A. Hatzelmann,et al.  Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics. , 2011, Handbook of experimental pharmacology.

[11]  M. Feldmann,et al.  Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis , 2010, Arthritis research & therapy.

[12]  N. J. Eungdamrong,et al.  Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. , 2010, The Journal of allergy and clinical immunology.

[13]  Toshihiko Ogura,et al.  Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.

[14]  Lei Wu,et al.  Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis , 2010, British Journal of Pharmacology.

[15]  M. Houslay Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. , 2010, Trends in biochemical sciences.

[16]  A. Gottlieb,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. , 2009, Journal of the American Academy of Dermatology.

[17]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[18]  P. Schafer,et al.  Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. , 2009, Journal of medicinal chemistry.

[19]  M. Pal,et al.  Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. , 2008, Journal of medicinal chemistry.

[20]  T. Tedder,et al.  Regulatory B cells as inhibitors of immune responses and inflammation , 2008, Immunological reviews.

[21]  George Muller,et al.  Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.

[22]  B. Strober,et al.  An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast* , 2008 .

[23]  D. Aronoff,et al.  Cyclic AMP: master regulator of innate immune cell function. , 2008, American journal of respiratory cell and molecular biology.

[24]  J. Beavo,et al.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. , 2007, Annual review of biochemistry.

[25]  G. Baillie,et al.  cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. , 2007, Circulation research.

[26]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[27]  G. Baillie,et al.  cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling. , 2006, Biochemical Society transactions.

[28]  Kam Y. J. Zhang,et al.  Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.

[29]  K. Vranizan,et al.  Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Baillie,et al.  Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[31]  G. Molostvov,et al.  The effects of selective cytokine inhibitory drugs (CC‐10004 and CC‐1088) on VEGF and IL‐6 expression and apoptosis in myeloma and endothelial cell co‐cultures , 2004, British journal of haematology.

[32]  K. Smith,et al.  Tracking antigen-specific lymphocytes in vivo. , 2004, Methods in molecular biology.

[33]  T. Okamoto,et al.  Inhibition of the NF-κB transcriptional activity by protein kinase A , 2002 .

[34]  M. Fresno,et al.  Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. , 2001, The Journal of pharmacology and experimental therapeutics.

[35]  M. Saraste,et al.  FEBS Lett , 2000 .

[36]  A. Olsen,et al.  Genomic organisation of the human cyclic AMP-specific phosphodiesterase PDE4C gene and its chromosomal localisation to 19p13.1, between RAB3A and JUND. , 1999, Cellular signalling.

[37]  P. Haslett,et al.  Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.

[38]  L. Corral,et al.  Thalidomide analogs and PDE4 inhibition. , 1998, Bioorganic & medicinal chemistry letters.

[39]  A. Olsen,et al.  Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2. , 1998, The Biochemical journal.

[40]  N. Mackman,et al.  Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. , 1997, Journal of immunology.

[41]  M. Conti,et al.  Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid. , 1997, Molecular pharmacology.

[42]  Nigel Mackman,et al.  Elevated Cyclic AMP Inhibits NF-κB-mediated Transcription in Human Monocytic Cells and Endothelial Cells* , 1996, The Journal of Biological Chemistry.

[43]  M. Conti,et al.  Identification of cyclic AMP‐phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells , 1996, FEBS letters.

[44]  M. Mclaughlin,et al.  A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. , 1993, The Journal of biological chemistry.